Clinical Trials Logo
  1. Home
  2. Epilepsy, Partial
  3. NCT00150709

A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy

Epilepsy, Partial Clinical Trial

Official title:
A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of The Safety And Efficacy Of Levetiracetam (Ucb L059) In Children With Epilepsy

Clinical Trial Summary

Open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until Levetiracetam (Keppra®) is approved for use in children or until the completion of the development program for pediatrics.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00150709
Study type Interventional
Source UCB Pharma
Contact
Status Completed
Phase Phase 3
Start date January 26, 1998
Completion date January 25, 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT00105040 - A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures Phase 2
Completed NCT00160615 - Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method Phase 3
Completed NCT00152516 - Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures Phase 3
Completed NCT00175890 - A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures. Phase 3
Completed NCT00113165 - Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures Phase 3
Withdrawn NCT01691872 - Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects Phase 1
Completed NCT00160654 - Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy Phase 4
Terminated NCT01545518 - IVIG Treatment for Refractory Immune-Related Adult Epilepsy Phase 2
Completed NCT00141414 - To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy. Phase 2
Completed NCT01332539 - An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy in Italy N/A
Completed NCT00355082 - Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy Phase 3
Completed NCT00152451 - Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures Phase 2
Withdrawn NCT02220972 - To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures Phase 4
Completed NCT00160628 - Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy Phase 3
Completed NCT00245713 - Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy. Phase 4
Terminated NCT01375374 - Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide Phase 3
Completed NCT00152373 - Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS Phase 3
Completed NCT00643500 - Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy Phase 4
Completed NCT00152503 - Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam Phase 2
Terminated NCT01891890 - Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE) Phase 3